FDA recalls 90,000 bottles of children's ibuprofen over contamination fears

FDA recalls 90,000 bottles of children's ibuprofen over contamination fears

A poster stating that in 2022, Big Pharma charged Americans two to three times more than other countries for the same drugs, with images of medication bottles and a syringe.

FDA recalls 90,000 bottles of children's ibuprofen over contamination fears

A major recall has been issued for nearly 90,000 bottles of Children's Ibuprofen Oral Suspension. The US Food and Drug Administration (FDA) announced the move after customers reported finding black particles and a gel-like substance in the medication. The affected product, a berry-flavoured solution for children aged 2 to 11, was manufactured in India by Strides Pharma Inc.

The recall began following multiple complaints about visible contamination in the liquid medicine. The FDA has labelled the action as precautionary, stating the risk of serious harm remains low. However, concerns over quality control have grown, as this is not the first issue linked to Strides Pharma.

Between March 2024 and March 2026, the company faced three other recalls worldwide. In August 2024, Enalapril Maleate Tablets were pulled from the US market due to an impurity called N-Nitroso-Enalapril. Five months later, Amoxicillin Capsules were recalled in India and the US after tests revealed microbial contamination. Most recently, in November 2025, Atenolol Tablets sold in the EU were found to contain less active ingredient than required. Neither Strides Pharma Inc. nor Taro Pharmaceuticals, the brand distributing the ibuprofen suspension, has publicly addressed the latest recall. The FDA continues to investigate the source of the contamination.

The recall highlights ongoing challenges in ensuring drug safety, especially for medicines used by children. With 90,000 bottles removed from shelves, regulators and manufacturers face pressure to strengthen quality checks. The FDA's classification of the recall as low-risk does not reduce the need for stricter oversight moving forward.

Neueste Nachrichten